Emergen-C Products
Allegations: Falsely marketing products as containing “Natural Flavors”
Robitussin Cough Medicine with DXM
Case Names (Date)
Bell et al. v. GlaxoSmithKline Consumer Healthcare Holdings (US) LLC et al.
21-cv-9454, C.D. Cal.
(Dec. 2021)
Calchi et al. v GlaxoSmithKline Consumer Healthcare Holdings (US) LLC et al.
22-cv-1341, S.D.N.Y.
(Feb. 2022)
Muller et al. v. GlaxoSmithKline Consumer Healthcare Holdings (US) LLC
22-cv-670, E.D. Mo.
(May 2022)
Papalia et al. v. GlaxoSmithKline Consumer Healthcare Holdings (US) LLC
22-cv-2630, S.D.N.Y.
(March 2022)
Product/Service
Robitussin cough medicine with dextromethorphan hydrobromide (DXM)
Allegations
Falsely marketing medicine as “Non-Drowsy” when the active ingredient causes drowsiness
Status
Bell case: Voluntarily dismissed
Calchi case: Claims against Pfizer were dismissed; Motion for preliminary approval of a settlement agreement that would resolve claims against GSK filed
Muller case: Pending
Papalia case: Consolidated with the Calchi case
Class-Action Tracker
ChapStick Natural Claims
Allegations: False natural claims
Emergen-C Dietary Supplements
Allegations: Misleadingly marketing that products are made with natural flavors
Mucinex, Tylenol, Sudafed PE, Robitussin, Theraflu, Vicks, and Other Cold and Flu Medicines
Allegations: Falsely marketing that medicines treat nasal congestion
Robitussin naturals Cough Relief – Honey and Ivy Leaf
Allegations: Misleadingly marketing the ingredients in and the health benefits provided by products
Sudafed PE, Tylenol Cold & Flu Severe, Benadryl Allergy Plus, Theraflu, NyQuil Severe Cold & Flu, and Walgreens
Allegations: Falsely marketing medicines as decongestants
Advil, Tylenol, DayQuil, NyQuil, TheraFlu, Sudafed, Robitussin, and Other Cold and Flu Medicines
Allegations: Falsely marketing that medicines treat congestion
Tylenol, TheraFlu, Mucinex, and Several Store Brands of Cold and Flu Medicines
Allegations: Falsely marketing medicines as nasal decongestants
Sudafed, NyQuil, Theraflu, Robitussin, Tylenol, Mucinex, and Several Store-brand Cold and Flu Medicines
Allegations: Falsely marketing medicines as nasal decongestants
Theraflu, Sudafed, Tylenol, and other Cold & Flu Medicines
Allegations: Falsely marketing medicines as decongestants
Sudafed, Tylenol, and Other Cold and Flu Medicines
Allegations: Falsely marketing products as decongestants
ChapStick Products
Allegations: False natural claims
Robitussin Non-Drowsy Claims
Allegations: Falsely marketing products as non-drowsy when an ingredient in them causes drowsiness
Abreva
Allegations: Misleadingly marketing Abreva cold sore treatments
Benefiber Prebiotic Supplement
In August 2020, a class-action lawsuit was filed against GlaxoSmithKline Consumer Healthcare for allegedly misleadingly advertising Benefiber Prebiotic Supplement as “100% Natural” when, according to plaintiffs, the company uses a…
Boostrix
In May 2020, a class-action lawsuit was filed against GlaxoSmithKline for allegedly falsely advertising the medication Boostrix in what has been referred to as “The Big Bad Cough” advertising campaign.…
Total Hydration ChapStick
December 2018: This case was voluntarily dismissed When a complaint is dismissed with prejudice, it cannot be refiled., the reasons for which have not been disclosed. September 2016: A class-action…
Chapstick Lip Balms with Sunscreen
In May 2019, a class-action lawsuit was filed against Wyeth Consumer Healthcare for allegedly misleadingly marketing – on the front of the package — that its Chapstick lip balm-sunscreen products…
The Latest
CATrends: OTC Cold and Flu Medicines Falsely Marketed as ‘Non-Drowsy’
Several products marketed as ‘non-drowsy’ contain an ingredient that causes drowsiness, lawsuits claim.
ChapStick Moisturizer
Lip balm’s own directions seem to contradict its “8 Hour Moisture” labeling claim.
Bagging Claims by Unofficial Oscar Swag Companies
Cue the play-off music.
The Lowdown on Low T
Is Big Pharma marketing a drug to help aging men with low sex drives or really selling a made-up disease?
Happy, Horny, Skinny Pill?
GSK will pay out $105 million in off-label use case.